Long-term safety and efficacy of lumacaftorivacaftor therapy in children aged 6-11 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a phase 3, open label, extension study

by Lwanda Ndwandwe

Enter your comment here...

Fill in your details below or click an icon to log in:

Email (required) (Address never made public)

Name (required)

Website

You are commenting using your WordPress.com account. ( Log Out / Change )

You are commenting using your Facebook account. ( Log Out / Change )

Connecting to %s

%d bloggers like this:

	Collet on pov: I am dating my proje…
	collet on Lessons learned
	collet on You need to be comfortable wit…
	collet on Beware of the ‘Silent killer’…
	Collet Dandara on Treating depression using…